Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer.
ALK
FDG-PET/CT
NSCLC
ROS1
crizotinib
therapeutic assessment
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
04
2021
accepted:
20
07
2021
entrez:
18
10
2021
pubmed:
19
10
2021
medline:
19
10
2021
Statut:
epublish
Résumé
Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have been reported in PROFILE studies with computed tomography (CT) evaluation. To date, only one case report of complete metabolic response on 2-deoxy-2-[
Identifiants
pubmed: 34660618
doi: 10.3389/fmed.2021.691253
pmc: PMC8514716
doi:
Types de publication
Case Reports
Langues
eng
Pagination
691253Informations de copyright
Copyright © 2021 Amrane, Campedel, Le Meur, Abgral, Kharroubi and Cadranel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Future Oncol. 2016 Aug;12(16):1911-28
pubmed: 27256160
Cancer Res. 2008 May 1;68(9):3389-95
pubmed: 18451166
Med Oncol. 2017 Sep 1;34(10):169
pubmed: 28864950
World J Radiol. 2014 Jul 28;6(7):392-8
pubmed: 25071879
Lancet Oncol. 2012 Oct;13(10):1011-9
pubmed: 22954507
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22
pubmed: 18089725
PLoS One. 2016 May 03;11(5):e0149955
pubmed: 27137772
Lung Cancer. 2013 Jul;81(1):142-3
pubmed: 23558310
Ann Oncol. 2019 Jul 1;30(7):1121-1126
pubmed: 30980071
Clin Nucl Med. 2020 Mar;45(3):209-210
pubmed: 31977471
N Engl J Med. 2010 Oct 28;363(18):1693-703
pubmed: 20979469
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):28-50
pubmed: 31637482
J Clin Oncol. 2012 Mar 10;30(8):863-70
pubmed: 22215748
J Thorac Oncol. 2017 Nov;12(11):1611-1625
pubmed: 28818606
J Clin Oncol. 2009 Sep 10;27(26):4247-53
pubmed: 19667264
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
Lung Cancer. 2020 Nov;149:137-143
pubmed: 33011375
J Clin Pathol. 2020 Feb;73(2):96-101
pubmed: 31562206
J Clin Oncol. 2018 Aug 1;36(22):2251-2258
pubmed: 29768118